271 related articles for article (PubMed ID: 21880588)
1. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.
Smith HA; Cronk RJ; Lang JM; McNeel DG
Cancer Res; 2011 Nov; 71(21):6785-95. PubMed ID: 21880588
[TBL] [Abstract][Full Text] [Related]
2. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
Smith HA; McNeel DG
J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines.
dos Santos NR; Torensma R; de Vries TJ; Schreurs MW; de Bruijn DR; Kater-Baats E; Ruiter DJ; Adema GJ; van Muijen GN; van Kessel AG
Cancer Res; 2000 Mar; 60(6):1654-62. PubMed ID: 10749136
[TBL] [Abstract][Full Text] [Related]
4. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
Dubovsky JA; McNeel DG
Prostate; 2007 Dec; 67(16):1781-90. PubMed ID: 17929270
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.
Smith HA; Rekoske BT; McNeel DG
Vaccine; 2014 Mar; 32(15):1707-15. PubMed ID: 24492013
[TBL] [Abstract][Full Text] [Related]
6. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
He Y; Mao L; Lin Z; Deng Y; Tang Y; Jiang M; Li W; Jia Z; Wang J; Ni B; Wu Y
Mol Immunol; 2008 May; 45(9):2455-64. PubMed ID: 18295890
[TBL] [Abstract][Full Text] [Related]
7. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
8. SSX: a multigene family with several members transcribed in normal testis and human cancer.
Gure AO; Türeci O; Sahin U; Tsang S; Scanlan MJ; Jäger E; Knuth A; Pfreundschuh M; Old LJ; Chen YT
Int J Cancer; 1997 Sep; 72(6):965-71. PubMed ID: 9378559
[TBL] [Abstract][Full Text] [Related]
9. The SSX family of cancer-testis antigens as target proteins for tumor therapy.
Smith HA; McNeel DG
Clin Dev Immunol; 2010; 2010():150591. PubMed ID: 20981248
[TBL] [Abstract][Full Text] [Related]
10. Inducible expression of cancer-testis antigens in human prostate cancer.
Heninger E; Krueger TE; Thiede SM; Sperger JM; Byers BL; Kircher MR; Kosoff D; Yang B; Jarrard DF; McNeel DG; Lang JM
Oncotarget; 2016 Dec; 7(51):84359-84374. PubMed ID: 27769045
[TBL] [Abstract][Full Text] [Related]
11. Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.
Godefroy E; Wang Y; Souleimanian NE; Scotto L; Stevanovic S; Chen YT; Valmori D; Ayyoub M
Cancer Immunol Immunother; 2007 Aug; 56(8):1183-92. PubMed ID: 17186289
[TBL] [Abstract][Full Text] [Related]
12. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
Wagner C; Neumann F; Kubuschok B; Regitz E; Mischo A; Stevanovic S; Friedrich M; Schmidt W; Rammensee HG; Pfreundschuh M
Cancer Immun; 2003 Dec; 3():18. PubMed ID: 14677925
[TBL] [Abstract][Full Text] [Related]
13. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
Taylor BJ; Reiman T; Pittman JA; Keats JJ; de Bruijn DR; Mant MJ; Belch AR; Pilarski LM
J Immunother; 2005; 28(6):564-75. PubMed ID: 16224274
[TBL] [Abstract][Full Text] [Related]
14. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
15. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
Ayyoub M; Stevanovic S; Sahin U; Guillaume P; Servis C; Rimoldi D; Valmori D; Romero P; Cerottini JC; Rammensee HG; Pfreundschuh M; Speiser D; Lévy F
J Immunol; 2002 Feb; 168(4):1717-22. PubMed ID: 11823502
[TBL] [Abstract][Full Text] [Related]
16. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.
Olson BM; McNeel DG
Cancer Immunol Immunother; 2011 Jun; 60(6):781-92. PubMed ID: 21350948
[TBL] [Abstract][Full Text] [Related]
17. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
Johnson LE; McNeel DG
Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020
[TBL] [Abstract][Full Text] [Related]
18. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.
Valmori D; Qian F; Ayyoub M; Renner C; Merlo A; Gnjatic S; Stockert E; Driscoll D; Lele S; Old LJ; Odunsi K
Clin Cancer Res; 2006 Jan; 12(2):398-404. PubMed ID: 16428478
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T cell responses to SSX-4 in melanoma patients.
Ayyoub M; Merlo A; Hesdorffer CS; Rimoldi D; Speiser D; Cerottini JC; Chen YT; Old LJ; Stevanovic S; Valmori D
J Immunol; 2005 Apr; 174(8):5092-9. PubMed ID: 15814740
[TBL] [Abstract][Full Text] [Related]
20. The SSX gene family: characterization of 9 complete genes.
Güre AO; Wei IJ; Old LJ; Chen YT
Int J Cancer; 2002 Oct; 101(5):448-53. PubMed ID: 12216073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
